secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0000950170-23-001981
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports Q1 net loss $29M; SPRINT Phase 2 COVID-19 study fully enrolled with data expected May 2023
--------------------------------------------------------------------------------

- Revenue $23.6M, down from $27.6M YoY, primarily from MAVYRET royalties.
- Net loss $29.0M ($1.39 loss per share) vs $30.1M ($1.48 loss per share) YoY.
- Cash $241.4M; expects runway into Q4 fiscal 2024.
- Enrollment complete in Phase 2 SPRINT study of EDP-235 (COVID-19); topline data expected May 2023.
- Expects Phase 1 data for EDP-323 (RSV) in Q2 2023; new PLpro and dual hMPV/RSV programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023001981/0000950170-23-001981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023001981/enta-20230207.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer